Roche Holding AG (0QOK.IL)
| Previous close | 280.30 |
| Open | 280.10 |
| Bid | 276.50 x N/A |
| Ask | 290.60 x N/A |
| Day's range | 278.70 - 286.30 |
| 52-week range | 90.40 - 286.30 |
| Volume | |
| Avg. volume | 261,635 |
| Market cap | 240.611B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 21.81 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 9.50 (3.99%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
- Globe Newswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
Group sales were up by 5%1 at constant exchange rates (CER) (stable in CHF) in the first half, driven by the high demand for both our medicines and diagnostics; excluding COVID-19-related products, sales increased by 8% Group sales growth accelerated to 9% (7% in CHF) in the second quarter as the decline in COVID-19-related sales no longer had an impact on overall salesPharmaceuticals Division sales rose by 5% in the first half; strong growth of 8% in the base business2 excluding COVID-19 effect
- Business Wire
New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
SOUTH SAN FRANCISCO, Calif., July 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies evaluating Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR), respectively, the two leading causes of vision loss in adults with diabetes. Susvimo is the first and only refillable eye implant that provides continuous delivery of a custom
- Globe Newswire
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were consistent with the known safety profile for Susvimo in people with DME and DRAdditionally, the US FDA has accepted the filing application for Susvimo in DME and DR based on one-year Pagoda and Pavilion study dataSusvimo is a unique therapeutic approach that provides continuous delivery of medicine to the e
